Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer, version 1.2020, 2020. Accessed 4/21/2020, https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
- Randomized trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension.Eur Urol. 2019; 76: 586-595https://doi.org/10.1016/j.eururo.2019.07.001
- Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.J Urol. 2009; 181: 956-962https://doi.org/10.1016/j.juro.2008.11.032
- Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.Eur Urol. 2014; 66: 243-250https://doi.org/10.1016/j.eururo.2014.03.011
- Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).Lancet (London, England). 2012; 380: 2018-2027https://doi.org/10.1016/s0140-6736(12)61253-7
- Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.Lancet Oncol. 2019; 20: 1740-1749https://doi.org/10.1016/s1470-2045(19)30486-3
- Radiation with or without antiandrogen therapy in recurrent prostate cancer.N Engl J Med. 2017; 376: 417-428https://doi.org/10.1056/NEJMoa1607529
- Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial.Int J Radiat Oncol*Biol*Phys. 2018; 102: 1605https://doi.org/10.1016/j.ijrobp.2018.08.052
- Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.J Clin Oncol. 2014; 32: 3939-3947https://doi.org/10.1200/JCO.2013.54.7893
- Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.Eur Urol. 2009; 55: 1003-1011https://doi.org/10.1016/j.eururo.2009.01.046
- Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.Eur Urol. 2011; 59: 832-840https://doi.org/10.1016/j.eururo.2011.02.024
- Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.J Natl Cancer Inst. 2015; 107https://doi.org/10.1093/jnci/djv119
- The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.Cancer. 2017; 123: 512-520
- Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.Lancet Oncol. 2006; 7: 472-479https://doi.org/10.1016/s1470-2045(06)70700-8
Granfors T, Modig H, Damber J-E, Tomic R. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. 2006;176:544-547. doi:10.1016/j.juro.2006.03.092w.
- Nonparametric estimation from incomplete observations.J Am Statist Assoc. 1958; 53: 457-481https://doi.org/10.2307/2281868
- Metastasis, mortality, and quality of life for men with NCCN high and very high risk localized prostate cancer following surgical and/or combined modality radiation therapies.Clin Genitourin Cancer. 2020; https://doi.org/10.1016/j.clgc.2019.11.023
- Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Stat Med. 1996; 15: 361-387https://doi.org/10.1002/(sici)1097-0258(19960229)15:4<361::Aid-sim168>3.0.Co;2-4
- A proportional hazards model for the subdistribution of a competing risk.J Am Statist Assoc. 1999; 94: 496-509
- Regression models and life-tables.J Royal Statist Soc Series B (Methodological). 1972; 34: 187-220
- Absolute versus relative benefit of androgen deprivation therapy for prostate cancer: moving beyond the hazard ratio to personalize therapy.Int J Radiat Oncol Biol Phys. 2020; 108: 899-902https://doi.org/10.1016/j.ijrobp.2020.06.011
- Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival.Eur Urol. 2015; 68: 777-784https://doi.org/10.1016/j.eururo.2015.04.035
- Temporal trends and predictors in diagnosing pathologic node-positive prostate cancer in clinically node-negative patients.Clin Genitourin Cancer. 2021; https://doi.org/10.1016/j.clgc.2021.05.003
- Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.Eur Urol. 2013; 63: 998-1008https://doi.org/10.1016/j.eururo.2012.10.036
- Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.Urology. 2001; 58: 233-239https://doi.org/10.1016/s0090-4295(01)01168-2
- Predicting survival of patients with node-positive prostate cancer following multimodal treatment.Eur Urol. 2014; 65: 554-562https://doi.org/10.1016/j.eururo.2013.09.025
- Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies.Eur Urol. 2018; 73 (Eur Urol. Jul 2018;74(1):e18-e19): 890-896https://doi.org/10.1016/j.eururo.2018.04.002
- Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy.BJU Int. 2013; 111: 1208-1214https://doi.org/10.1111/bju.12079
- The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients.Eur Urol. 2016; 69: 1142-1148https://doi.org/10.1016/j.eururo.2015.12.010
- Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.J Urol. 2007; 178 (discussion 870-1): 864-870https://doi.org/10.1016/j.juro.2007.05.048
- Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.Eur Urol. 2009; 55: 261-270https://doi.org/10.1016/j.eururo.2008.09.043
- Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.J Urol. 2004; 172: 2252-2255https://doi.org/10.1097/01.ju.0000143448.04161.cc
- Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients.J Cancer. 2019; 10: 2237-2242https://doi.org/10.7150/jca.29714
- Lymph node ratio determines the benefit of adjuvant radiotherapy in pathologically 3 or less lymph node-positive prostate cancer after radical prostatectomy: a population-based analysis with propensity-score matching.Oncotarget. 2017; 8: 110625-110634https://doi.org/10.18632/oncotarget.22610
- Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.J Clin Oncol. 2007; 25: 2035-2041https://doi.org/10.1200/JCO.2006.08.9607
- Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy.J Clin Oncol. 2016; 34: 3648-3654https://doi.org/10.1200/JCO.2016.67.9647
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer.